±èÂù
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : ´ëÀå¾Ï, ºñ´¢±â¾Ï(½ÅÀå¾Ï, ¹æ±¤¾Ï)
Á÷
ˤ
: ºÎ±³¼ö
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
12
ÇØ¿Ü
Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption. Cancer Cell 2014 (IF 24.755)
11
ÇØ¿Ü
Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. BMC Cancer 2013 (IF 3.319)
10
ÇØ¿Ü
Soluble Vascular Endothelial Growth Factor Receptor-3 Suppresses Lymphangiogenesis and Lymphatic Metastasis in Bladder Cancer. Molecular Cancer 2011 (IF 5.888)
9
ÇØ¿Ü
Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites. Cancer Research and Treatment 2010 (IF 4.245)
8
ÇØ¿Ü
Signet Ring Cell Carcinoma of the Extrahepatic Bile Duct. Gut and Liver 2010 (IF 2.000)
7
±¹³»
A case of nephrogenic systemic fibrosis after gadolinium-based contrast agent injection. Korean J Med. 2010
6
ÇØ¿Ü
Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. Cancer Chemother. Pharmacol. 2010 (IF 2.571)
5
ÇØ¿Ü
Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. Cancer Research and Treatment 2009 (IF 4.245)
4
ÇØ¿Ü
Clinical value of ezrin expression in primary osteosarcoma. Cancer Research and Treatment 2009 (IF 4.245)
3
ÇØ¿Ü
Prognosis of pN3 stage gastric cancer. Cancer Research and Treatment 2009 (IF 4.245)
1
2
3
4
5
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729